Drugs / pegcrisantaspase
pegcrisantaspase
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04526795 | Apr 2021 → Nov 2024 | T-cell prolymphocytic leukemia, acute biphenotypic leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT04666649 | Mar 2021 → Sep 2024 | acute myeloid leukemia | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 1 | NCT01551524 | Mar 2012 → Feb 2015 | hematopoietic and lymphoid cell neoplasm | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02257684 | Sep 2014 → Feb 2015 | acute lymphoblastic leukemia, lymphoblastic lymphoma | Jazz Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-11-30 | Jazz Pharmaceuticals | Results Jazz Pharmaceuticals to Present New Data Highlighting Advancements in Solid Tumors and Rare Blood Cancers at Upcoming Oncology Meetings jazzpharma.com ↗
Overcoming Venetoclax (Ven) Resistance Through Glutamine (Gln) Depletion: Final Analysis of the Phase 1 Trial of Ven and Pegcrisantaspase (PegC) Combination in Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) |
| 2019-08-06 | Jazz Pharmaceuticals | Results Jazz Pharmaceuticals Advances Recombinant Crisantaspase Development Program jazzpharma.com ↗
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Phase 1 study of its recombinant crisantaspase molecule, JZP-458, met its efficacy and safety objectives. |
All press releases naming this drug 4 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pegcrisantaspase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04666649 ↗ |
| Known as | crisantaspase | “long-acting crisantaspase (pegcrisantaspase [PegC])” PMID 39437546 ↗ Jan 2025 |
| Known as | mPEG-r-crisantaspase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01551524 ↗ |
| Known as | PegC | “long-acting crisantaspase (pegcrisantaspase [PegC])” PMID 39437546 ↗ Jan 2025 |
| Route | Intravenous | “IV infusion over 60 minutes” NCT01551524 ↗ |